Press Releases

10.27.2026

Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma

10.26.2026

Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting

10.24.2026

Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026

10.14.2026

Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026

10.07.2026

Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer

10.06.2026

Pfizer Declares Fourth-Quarter 2026 Dividend

10.02.2026

Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo

10.01.2026

Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

09.28.2026

Pfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO

09.22.2026

Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts

09.15.2026

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

09.08.2026

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference